Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, CHAMPIONS ONCOLOGY, INC. reported revenue of $57M, up 13.5% year over year. Operating margin was 8.0% and net margin 8.3%, on a free-cash-flow margin of 12.3% with capital expenditure at 0.7% of revenue. Every figure is computed directly from CSBR's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $57M | 8.0% | 8.3% |
| FY2024 | $50M | -14.7% | -14.5% |
| FY2023 | $54M | -9.8% | -9.9% |
| FY2022 | $49M | 1.2% | 1.1% |
| FY2021 | $41M | 0.9% | 0.9% |
How does CSBR compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.